Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $864 | $695 | $451 | $577 |
| - Cash | $135 | $150 | $212 | $297 |
| + Debt | $3 | $574 | $565 | $202 |
| Enterprise Value | $731 | $1,120 | $804 | $482 |
| Revenue | $50 | $40 | $29 | $30 |
| % Growth | 25.3% | 38.5% | -3.9% | – |
| Gross Profit | $43 | $34 | $25 | $26 |
| % Margin | 87.5% | 87.2% | 86.9% | 87.1% |
| EBITDA | -$14 | -$58 | -$76 | -$56 |
| % Margin | -27.7% | -147.1% | -266.7% | -187.7% |
| Net Income | -$30 | -$76 | -$94 | -$74 |
| % Margin | -60.5% | -191.9% | -330.7% | -251% |
| EPS Diluted | -0.41 | -1.05 | -1.31 | -1.05 |
| % Growth | 61% | 19.8% | -24.8% | – |
| Operating Cash Flow | -$14 | -$63 | -$85 | -$63 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$14 | -$63 | -$85 | -$63 |